Inhibitor Therapeutics, Inc.
INTINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for INTI. That does not mean none is planned.
Get an email about INTI's next catalysts
Track Inhibitor Therapeutics (INTI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
No drugs found in this phase.
Hormone receptor-positive, HER2-negative metastatic breast cancer
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
1 drug in this indication
nonsegmental vitiligo
1 drug in this indication
FLT3-mutated acute myeloid leukemia
1 drug in this indication
ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
1 drug in this indication
gout / hyperuricemia (serum urate lowering)
1 drug in this indication
locally advanced or metastatic urothelial cancer after platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Inhibitor Therapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Inhibitor Therapeutics, Inc. (INTI) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track INTI biotech catalysts?β
Add INTI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inhibitor Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
